Roflumilast and TMS Motor Plasticity

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

June 30, 2026

Conditions
Other Conditions of Brain
Interventions
DRUG

Roflumilast

Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

DRUG

Placebo

Participants will ingest either a placebo or roflumilast 500mg in a single blind crossover study and receive transcranial magnetic stimulation to the primary motor cortex.

DEVICE

Intermittent theta-burst stimulation transcranial magnetic stimulation

Intermittent theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 190 seconds.

DEVICE

Continuous theta-burst stimulation transcranial magnetic stimulation

Continuous theta-burst stimulation consists of 2 second trains every 10 seconds. Each train is composed of 3 pulses at 50Hz, 200 milliseconds intervals given at 80% resting motor threshold. The total time for this treatment stimulus is 600 pulses over 40 seconds.

Trial Locations (1)

T2N 1N4

University of Calgary, Calgary

All Listed Sponsors
lead

University of Calgary

OTHER

NCT06457191 - Roflumilast and TMS Motor Plasticity | Biotech Hunter | Biotech Hunter